Dr. Weeks’ Comments: Now we are learning that statin drugs may help people with cancer. That is a logical assertion because the only significant beneficial method of action for a statin drug is that it is a weak anti-inflammatory agent. The benefit that statins offer to cardiac patients has less to do with lowering cholesterol than it does lowering inflammation. That said, there’re so many better options for lowering inflammation in a cardiac patient that statins should never be prescribed for this purpose. Why use an agent which lowers inflammation weekly while strongly inhibiting the body’s ability to generate energy (it blocks Co Q 10) when there are natural products like Soul which are very powerful yet safe anti-inflammatory agents.
Now readers have heard me say over the years that the secret for preventing the spread of cancer- the secret for blocking metastasis- is anti-inflammation. Since the statins are weak anti-inflammatory agents they will have a weak benefit for cancer patients. The conclusion of this large study was stands were associated but not causally related to improvements and outcomes. If this same study were done using Soul, I guarantee it would’ve been a very positive study.
Postdiagnosis Statin Use and Mortality in Danish Patients With Prostate Cancer
Increasing evidence indicates that statin use may reduce mortality from prostate cancer. In this work, we examined whether postdiagnosis statin use was associated with reduced cancer-specific mortality or all-cause mortality among patients with prostate cancer in Denmark.
METHODS From nationwide Danish registries, we identified all patients with incident prostate adenocarcinoma from 1998 to 2011 and retrieved data on tumor and patient characteristics, drug use, and primary treatment. We defined postdiagnosis use (two or more prescriptions) of statins as a time-varying covariate with 1-year lag. Cox proportional hazards regression models used to compute hazard ratios (HRs) for prostate cancer–specific mortality and all-cause mortality through 2013 associated with postdiagnosis statin use. In secondary and sensitivity analyses, we assessed statin use within exposure periods of 1 year or 5 years after prostate cancer diagnosis and evaluated the influence of prediagnosis statin use.
Among 31,790 patients, 7,365 died of prostate cancer and 11,811 died from other causes during a median follow-up of 2.8 years (interquartile range, 1.3 to 5.1 years) from 1 year after diagnosis. Postdiagnosis statin use was associated with adjusted HRs of 0.83 (95% CI, 0.77 to 0.89) for prostate cancer mortality and 0.81 (95% CI, 0.76 to 0.85) for all-cause mortality. Similar results were observed in 1-year and 5-year sensitivity analyses. No substantial effect measure modification was found with estimated dose or type of statin, clinical stage, Gleason score, or with prediagnosis statin use; however, patients who were diagnosed early in the study period or who underwent radical prostatectomy or endocrine therapy exhibited slightly lower HRs for prostate cancer mortality with postdiagnosis statin use than did those in the overall analyses.
CONCLUSION Postdiagnosis statin use was associated with reduced mortality from prostate cancer; however, it remains to be established whether this association is causal.